2015
Unresectable intrahepatic cholangiocarcinoma: Systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone
Konstantinidis I, Groot Koerkamp B, Do R, Gönen M, Fong Y, Allen P, D'Angelica M, Kingham T, DeMatteo R, Klimstra D, Kemeny N, Jarnagin W. Unresectable intrahepatic cholangiocarcinoma: Systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone. Cancer 2015, 122: 758-765. PMID: 26695839, PMCID: PMC4764409, DOI: 10.1002/cncr.29824.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBile Duct NeoplasmsBile Ducts, IntrahepaticCamptothecinCholangiocarcinomaDeoxycytidineDisease-Free SurvivalFemaleFloxuridineFluorouracilGemcitabineHepatic ArteryHumansInfusions, Intra-ArterialIrinotecanMaleMiddle AgedMitomycinRetrospective StudiesSurvival RateConceptsHepatic arterial infusionHepatic arterial infusion chemotherapySystemic chemotherapyIntrahepatic cholangiocarcinomaOverall survivalUnresectable tumorsPatients treated with systemic chemotherapyCombination groupCombination of systemic chemotherapyMemorial Sloan Kettering Cancer CenterAssociated with longer survivalAssociated with poor survivalMedian overall survivalUnresectable intrahepatic cholangiocarcinomaArterial infusion chemotherapyLymph node diseaseOutcomes of patientsLog-rank testKaplan-Meier analysisAssociated with greater survivalComplete resectionInfusion chemotherapyConsecutive patientsNode diseaseArterial infusion
2013
Hepatic arterial infusion for unresectable intrahepatic cholangiocarcinoma: An update on survival from two prospective clinical trials.
Konstantinidis I, Do R, Gultekin D, Gonen M, Schwartz L, Fong Y, Allen P, D'Angelica M, DeMatteo R, Klimstra D, Kemeny N, Jarnagin W. Hepatic arterial infusion for unresectable intrahepatic cholangiocarcinoma: An update on survival from two prospective clinical trials. Journal Of Clinical Oncology 2013, 31: 4116-4116. DOI: 10.1200/jco.2013.31.15_suppl.4116.Peer-Reviewed Original ResearchHepatic arterial infusionUnresectable intrahepatic cholangiocarcinomaPre-treatment DCE-MRIIntrahepatic cholangiocarcinomaDCE-MRIArterial infusionClinical trialsHepatic arterial infusion chemotherapyAdvanced intrahepatic cholangiocarcinomaDied of diseaseLong-term outcomesStable diseasePartial responseMedian survivalTumor perfusionProlonged survivalTumor perfusion dataPoor survivalFollow-upPatientsDynamic contrastLiver progressionPerfusion dataSurvival dataSurvival
2012
Pathologic Response to Preoperative Chemotherapy in Colorectal Liver Metastases: Fibrosis, not Necrosis, Predicts Outcome
Poultsides G, Bao F, Servais E, Hernandez-Boussard T, DeMatteo R, Allen P, Fong Y, Kemeny N, Saltz L, Klimstra D, Jarnagin W, Shia J, D’Angelica M. Pathologic Response to Preoperative Chemotherapy in Colorectal Liver Metastases: Fibrosis, not Necrosis, Predicts Outcome. Annals Of Surgical Oncology 2012, 19: 2797-2804. PMID: 22476753, DOI: 10.1245/s10434-012-2335-1.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCamptothecinChemotherapy, AdjuvantColorectal NeoplasmsFemaleFibrosisHepatectomyHumansIrinotecanKaplan-Meier EstimateLiver NeoplasmsMaleMiddle AgedMucinsMultivariate AnalysisNecrosisOrganoplatinum CompoundsOxaliplatinPreoperative CarePrognosisRetrospective StudiesSingle-Blind MethodConceptsColorectal liver metastasis resectionColorectal liver metastasesPreoperative chemotherapyPathological responseAcellular mucinHepatic arterial infusion chemotherapyResponse to preoperative chemotherapyAssociation of treatment responseArterial infusion chemotherapyDisease-specific survivalAssociated with survivalRate of necrosisInfusion chemotherapyLiver metastasesTreatment responseChemotherapyFibrosisPercentage necrosisResectionPatientsChemotherapy patientsNecrosisPathological alterationsPredicting OutcomeDominant response patterns
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply